

2023 CGM Update

With the start of 2023, a few minor changes have been made in regards to the Dexcom G6 product coverage, the Dexcom G7 anticipated availability, and Freestyle Libre system access:

- The Dexcom G6 is now able to be filled in a community pharmacy setting under United Healthcare Medicare plans.
- The Dexcom G7 device was approved by the FDA on December 8, 2022, and is expected to be available in the early months of 2023, with no current payer eligibility information available.
- There have been no changes to the Freestyle Libre payer eligibility.
- Samples for the Freestyle Libre 3 system are available through Abbott. These may be obtained two different ways:
 - Samples can be provided by requesting directly from the local Freestyle Libre representative (information may be provided upon request).
 - Patients are able to enroll in a free trial by visiting the website <https://www.freestyle.abbott/us-en/myfreestyle.html> and filling out the requested information.
- Prescriptions for the Freestyle Libre 3 may be sent to a community pharmacy, however product availability is limited and can currently be filled through CVS and Walgreen's Pharmacies as of January 2023.
- On plans with Libre coverage, the Freestyle Libre 2 and Freestyle Libre 3 systems are within the same tier and price, and should not require a prior authorization when switching between the two system generations.
- As of January 1, 2023, New York State Medicaid Fee for Service has altered the HCPCS coding for both Dexcom and Freestyle products. Previously used "K" codes have been replaced with new "A" and "E" billing codes. Further information on the specific coding is available upon request, or by visiting the New York State Medicaid website www.emedny.org/ProviderManuals/communications/2023_Coding_Changes_for_Continuous_Glucose_Monitoring_-_12-30-22.pdf

For a comprehensive comparison and description of the different CGM products currently available, please refer to the 2022 CGM Review, released in November 2022.



CGM Coverage and Pharmacy Access

Of note, this is not a comprehensive list and is current as of January 2023. Plans may require prior authorization or step therapy prior to coverage of a continuous glucose monitor. While not ubiquitous across all payers, most plans require clinical documentation supporting use with a CMN, requiring chart notes that speak to current blood glucose monitoring frequency (usually requires documentation of at least 4 times per day testing), and insulin injection frequency and dose (usually requires use of both bolus and basal insulin, or insulin pump; most plans require at least 2 injections of bolus insulin per day and/or documented “frequent self-adjustments of insulin”, e.g. use of a sliding scale). Specific questions related to each product and payer can be directed to the GLIN Pharmacy Team for review.

DME Supplier/Email	Phone/FAX	Payer Eligibility
Advanced Diabetes Supply customer@northcoastmed.com	P: 866-422-4866 F: 760-496-0234	Fidelis Care Highmark BCBS of WNY United Healthcare
Better Living Now info@betterlivingnow.com	P: 800-854-5729 F: 800-654-7515	Fidelis Care Highmark BCBS of WNY Independent Health Molina Healthcare United Healthcare Univera
Bridgewater Health Supplies info@bridgewaterhealthsupplies.com	P: 888-763-5611 F: 877-297-5127	Fidelis Care Highmark BCBS of WNY Independent Health Molina Healthcare
Byram Healthcare AbbottReferrals@byramhealthcare.com	P: 877-633-4225 F: 866-387-1127	Highmark BCBS of WNY Molina Healthcare United Healthcare Univera Healthcare
CCS Medical help@ccsmed.com	P: 888-633-4225 F: 800-557-8256	Independent Health Univera Healthcare
Edgepark Medical Supplies	P: 888-394-5375 F: 614-553-5790	Fidelis Care Highmark BCBS of WNY Molina Healthcare United Healthcare
US Med	P: 866-723-6958 F: 866-347-8544	Fidelis Care Highmark BCBS of WNY Independent Health Association
Pharmacy Coverage		Highmark Independent Health Molina United Healthcare



References:

1. Dexcom G7 receives FDA clearance: The most accurate continuous glucose monitoring system cleared in the U.S. DexCom, Inc. - Dexcom G7 Receives FDA Clearance: The Most Accurate Continuous Glucose Monitoring System Cleared in the U.S. https://investors.dexcom.com/news/news-details/2022/Dexcom-G7-Receives-FDA-Clearance-The-Most-Accurate-Continuous-Glucose-Monitoring-System-Cleared-in-the-U.S/default.aspx?_gl=1*1nhmcqz*_ga*MzUxOTQzMzIOLjE2NzMwMjcxMDI.*_ga_S6J885VKT2*MTY3MzAyNzEwMi4xLjAuMTY3MzAyNzEwMi4wLjAuMA..*_ga_KQDZFFW8BJ*MTY3MzAyNzEwMi4xLjAuMTY3MzAyNzEwMi4wLjAuMA..&_ga=2.52795496.1796312495.1673027103-351943324.1673027102 Published December 8, 2022. Accessed January 6, 2023.

